Business
WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), recently hosted its third CRDMO Day in Tokyo, bringing together senior leaders and experts from Japan's biopharmaceutical industry, exchanging the latest market insights and best practices in advancing biologics innovation from IND to commercialization. Leveraging its world-class quality systems, operational excellence, and innovative technologies, WuXi Biologics accelerates and tran
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"TOKYO, May 20, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), recently hosted its third CRDMO Day in Tokyo, bringing together senior leaders and experts from Japan's biopharmaceutical industry, exchanging the latest market insights and best practices in advancing biologics innovation from IND to commercialization. Leveraging its world-class quality systems, operational excellence, and innovative technologies, WuXi Biologics accelerates and transforms the discovery, development, and manufacturing of biologics across the entire value chain in Japan.","length":645,"tagName":"p"},{"type":"text","content":"With the theme "Ignite Future: CRDMO Day Tokyo 2026," the gathering convened senior executives and experts from WuXi Biologics for in-depth dialogues with its Japanese partners. Discussions spanned the latest market insights and industry dynamics, integrated solutions for complex modalities, CMC best practices and manufacturing excellence. Together, the sessions highlighted not only the opportunities emerging in Japan's biopharmaceutical industry but also the breadth and depth of WuXi Biologics' capabilities in supporting them.","length":551,"tagName":"p"},{"type":"text","content":"Dr. Chris Chen, CEO of WuXi Biologics, commented: "Backed by deep expertise and an established track record, we look forward to deepening our collaboration with Japanese biopharmaceutical companies across the full lifecycle of a molecule, from research and development through to manufacturing, especially in the complex modalities where Japan is at the forefront of global innovation. We will continue to invest in the capabilities and talent required to support that vision over the long term, positioning ourselves as a trusted partner in shaping Japan's biopharmaceutical future."","length":598,"tagName":"p"},{"type":"text","content":"That commitment is underwritten by a global platform built for scale and complexity. WuXi Biologics continues to advance its "Global Dual Sourcing" strategy and to strengthen its integrated CRDMO capabilities, while extending its manufacturing footprint across the United States, Ireland, Germany, China, Singapore, and Qatar.","length":336,"tagName":"p"},{"type":"text","content":"WuXi Biologics i...